THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE

Show other versions (1)

The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 test...

Full description

Bibliographic Details
Main Authors:	K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	resistance to clopidogrel pharmacogenetics cyp2c19
Online Access:	https://www.rpcardio.online/jour/article/view/99

Similar Items

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics
by: Arzu Gunes, et al.
Published: (2010-03-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM
by: Ekaterina S. Kropacheva
Published: (2018-12-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
by: Gower MN, et al.
Published: (2020-07-01)

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
by: D. A. Sychev, et al.
Published: (2015-09-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
by: M. A. Andreyanova, et al.
Published: (2018-11-01)

CYP2C19 gene polymorphism and its impact on the long-term prognosis after myocardial infarction
by: Mariya V. Solodun, et al.
Published: (2022-07-01)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
by: Nizamuddin S, et al.
Published: (2021-01-01)

Association of CYP2C19*2 c.681G>A (rs4244285) Loss-of-function Allele with Cardiovascular Disease Risk in the Kosovo Population
by: Elshani N, et al.
Published: (2025-03-01)

CYP2C19 polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome
by: Mirzaev KB, et al.
Published: (2017-04-01)

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
by: Qamar Shubbar, et al.
Published: (2024-02-01)

Pharmacogenetics of warfarin: A literature review
by: Nadezhda V. Izmozherova, et al.
Published: (2024-11-01)

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel
by: Nestorovska KA, et al.
Published: (2024-03-01)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
by: Rafael eDe La Torre, et al.
Published: (2012-11-01)

The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis
by: Abdullah N. Alkattan, et al.
Published: (2022-06-01)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
by: Bhawani Yasassri Alvitigala, et al.
Published: (2020-12-01)

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA
by: K. B. Mirzaev, et al.
Published: (2015-10-01)

VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY
by: D. A. Sychev, et al.
Published: (2015-12-01)

Pharmacogenetics: Influence of CYP2C9*2 and *3 alleles polymorphisms on Iraqi type 2 diabetic patients
by: Ghada S. Rasool, et al.
Published: (2024-01-01)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
by: Xiujin Shi, et al.
Published: (2021-06-01)

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese
by: Chow E, et al.
Published: (2020-01-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
by: Yujing Cheng, et al.
Published: (2023-01-01)

The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance
by: Rakićević Ljiljana, et al.
Published: (2022-01-01)

Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard
by: Mohammad A. Alshabeeb, et al.
Published: (2022-08-01)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
by: Rahel Tekeste, et al.
Published: (2022-04-01)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023-11-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
by: Kayla R. Tunehag, et al.
Published: (2025-01-01)

Clinical pharmacogenetics of antiaggregants: clinical pharmacologist' point of view
by: D. A. Syche, et al.
Published: (2007-08-01)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
by: Nita A Limdi, et al.
Published: (2012-10-01)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
by: Julia Carolin Stingl, et al.
Published: (2022-12-01)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
by: Changqing Li, et al.
Published: (2021-03-01)

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
by: Anh B. Nguyen, et al.
Published: (2022-08-01)